Results 11 to 20 of about 19,806 (216)
The Nexus of cfDNA and Nuclease Biology [PDF]
Trends in Genetics, 2021 Cell-free DNA (cfDNA) is a widely used noninvasive biomarker for diagnosis and prognosis of multiple disease states. Emerging evidence suggests that cfDNA might not just be passive waste products of cell death but could have a physiological and pathological function in inflammation and autoimmunity.
Diana S.C. Han, Y.M. Dennis Lo
openaire +2 more sources
Plasma cfDNA in Glioblastoma—Letter [PDF]
Clinical Cancer Research, 2020 We read enthusiastically the recent article by Bagley and colleagues ([1][1]). The authors prospectively investigated plasma cell-free DNA (cfDNA) concentration and mutations in patients with glioblastoma. This is an interesting topic and we commend the authors for their efforts.
Takeshi, Takayasu +2 more
openaire +2 more sources
Plasma cfDNA in Glioblastoma—Response
Clinical Cancer Research, 2020 We appreciate the interest in our study from Takayasu and colleagues. They raise important issues which were largely addressed in our article but deserve further discussion. Takayasu and colleagues question whether variants detected in plasma in our study reflect tumor somatic mutations.
Stephen J, Bagley, Erica L, Carpenter
openaire +3 more sources
NICE: A Two-Step Non-Invasive Framework for Embryo cfDNA Read Enrichment and Quality Assessment. [PDF]
Adv Sci (Weinh)The non‐invasive NICE framework, built on an ensemble stacking machine learning model, prioritizes embryos by analyzing cell‐free DNA from spent culture medium. By integrating multimodal signals, including genomic and epigenetic profiles, this automated approach standardizes morphological assessment without human bias, paving the way for more precise ...
Zhou X +6 more
europepmc +2 more sources
Cancer Research, Statistics, and Treatment, 2019 Background: Outcomes based on liquid biopsy in poor performance, older, biopsy-ineligible advanced non-small cell lung cancer (NSCLC) patients are unknown.
Avinash Pandey +4 more
doaj +1 more source
Unveiling the Prognostic Power of Circulating Tumor DNA in Multiple Myeloma: A Systematic Review and Updated Meta-Analysis. [PDF]
Cancer MedABSTRACT Circulating tumor DNA (ctDNA) serves as a non‐invasive liquid biopsy technique, offering potential utility in the prognostic evaluation of multiple myeloma (MM). In this study, we performed a systematic review and updated meta‐analysis to analyze the association between ctDNA and the prognosis of patients diagnosed with MM.
Ying W, Fan L, Li R, Qu X.
europepmc +2 more sources
cfDNA Sequencing: Technological Approaches and Bioinformatic Issues [PDF]
Pharmaceuticals, 2021 In the era of precision medicine, it is crucial to identify molecular alterations that will guide the therapeutic management of patients. In this context, circulating tumoral DNA (ctDNA) released by the tumor in body fluids, like blood, and carrying its molecular characteristics is becoming a powerful biomarker for non-invasive detection and monitoring
Elodie Bohers +2 more
openaire +5 more sources
Evaluating liquid biopsies for methylomic profiling of prostate cancer
Epigenetics, 2020 Background: Liquid biopsies offer significant potential for informing on cancer progression and therapeutic resistance via minimally invasive serial monitoring of genetic alterations.
Romina Silva +9 more
doaj +1 more source
Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome
Epigenetics, 2021 The methylation pattern of cfDNA, isolated from liquid biopsies, is gaining substantial interest for diagnosis and monitoring of diseases. We have evaluated the impact of type of blood collection tube and time delay between blood draw and plasma ...
Ruben Van Paemel +7 more
doaj +1 more source
Infection and Drug Resistance, 2023 Yanfei Lu,1,2,* Wenying Xia,1,2,* Shuxian Miao,1,2 Min Wang,1,2 Lei Wu,1,2 Ting Xu,1,2 Fang Wang,1,2 Jian Xu,1,2 Yuan Mu,1,2 Bingfeng Zhang,1,2 Shiyang Pan1,2 1Department of Laboratory Medicine, Jiangsu Province Hospital and Nanjing Medical ...
Lu Y +10 more
doaj